$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000154908423000011 Filed on March 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$4.122M	$3.551M	$12.91M
YoY Change	60.58%	-12.88%	14.81%
Cost Of Revenue	$2.122M	$1.873M	$6.698M
YoY Change	56.26%	12.76%	48.94%
Gross Profit	$2.000M	$1.678M	$6.214M
YoY Change	65.43%	-30.52%	-7.93%
Gross Profit Margin	48.52%	47.25%	48.13%
Selling, General & Admin	$5.294M	$5.343M	$18.14M
YoY Change	19.05%	-13.11%	1.77%
% of Gross Profit	264.7%	318.41%	291.99%
Research & Development	$1.154M	$771.0K	$3.626M
YoY Change	15.52%	-5.75%	31.95%
% of Gross Profit	57.7%	45.95%	58.35%
Depreciation & Amortization	$414.0K	$255.0K	$887.0K
YoY Change	216.03%	96.15%	58.11%
% of Gross Profit	20.7%	15.2%	14.27%
Operating Expenses	$6.448M	$6.114M	$21.77M
YoY Change	18.4%	-12.24%	5.8%
Operating Profit	-$4.448M	-$4.436M	-$15.56M
YoY Change	4.98%	-2.55%	12.5%
Interest Expense	$127.0K	$983.0K	$156.0K
YoY Change	370.37%	-516.53%	38.05%
% of Operating Profit
Other Income/Expense, Net	$59.00K	$275.0K	$476.0K
YoY Change	-115.4%	-85.71%	-88.29%
Pretax Income	-$4.389M	-$3.178M	-$15.08M
YoY Change	-5.0%	11.0%	54.44%
Income Tax
% Of Pretax Income
Net Earnings	-$4.389M	-$3.178M	-$15.08M
YoY Change	-5.0%	11.0%	54.44%
Net Earnings / Revenue	-106.48%	-89.5%	-116.79%
Basic Earnings Per Share	-$0.33		-$1.16
Diluted Earnings Per Share	-$0.33	-$0.24	-$1.16
COMMON SHARES
Basic Shares Outstanding	13.34M shares	13.14M shares	12.96M shares
Diluted Shares Outstanding	13.30M shares		12.96M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.28M	$20.53M	$20.53M
YoY Change	-55.01%	-49.2%	-49.2%
Cash & Equivalents	$16.28M	$20.53M
Short-Term Investments
Other Short-Term Assets	$831.0K	$700.0K	$700.0K
YoY Change	0.24%	44.33%	44.33%
Inventory	$5.662M	$5.187M	$5.187M
Prepaid Expenses
Receivables	$4.827M	$4.625M	$4.625M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.60M	$31.04M	$31.04M
YoY Change	-36.0%	-35.06%	-35.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.454M	$2.680M	$3.987M
YoY Change	176.98%	170.43%	230.32%
Goodwill	$431.0K	$431.0K
YoY Change
Intangibles	$5.136M	$5.217M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$258.0K	$231.0K	$231.0K
YoY Change	82.98%	40.85%	40.85%
Total Long-Term Assets	$9.507M	$9.866M	$9.866M
YoY Change	749.6%	619.62%	619.62%
TOTAL ASSETS
Total Short-Term Assets	$27.60M	$31.04M	$31.04M
Total Long-Term Assets	$9.507M	$9.866M	$9.866M
Total Assets	$37.10M	$40.90M	$40.90M
YoY Change	-16.13%	-16.81%	-16.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.042M	$3.151M	$3.151M
YoY Change	3.5%	1.42%	1.42%
Accrued Expenses	$2.227M	$2.278M	$2.619M
YoY Change	22.43%	-0.91%	7.38%
Deferred Revenue	$1.296M	$1.121M
YoY Change	16.23%	-8.11%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.623M	$2.310M	$2.310M
YoY Change
Total Short-Term Liabilities	$9.537M	$9.201M	$9.201M
YoY Change	59.75%	34.22%	34.22%
LONG-TERM LIABILITIES
Long-Term Debt	$3.534M	$3.767M	$3.767M
YoY Change	77.23%	89.01%	89.01%
Other Long-Term Liabilities	$125.0K	$141.0K	$2.493M
YoY Change	108.33%	90.54%	-19.55%
Total Long-Term Liabilities	$125.0K	$141.0K	$6.260M
YoY Change	-93.91%	-93.18%	22.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.537M	$9.201M	$9.201M
Total Long-Term Liabilities	$125.0K	$141.0K	$6.260M
Total Liabilities	$15.82M	$15.46M	$15.46M
YoY Change	47.09%	29.41%	29.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$228.3M	-$223.9M
YoY Change	6.96%	7.22%
Common Stock	$13.00K	$13.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.28M	$25.44M	$25.44M
YoY Change
Total Liabilities & Shareholders Equity	$37.10M	$40.90M	$40.90M
YoY Change	-16.13%	-16.81%	-16.81%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.389M	-$3.178M	-$15.08M
YoY Change	-5.0%	11.0%	54.44%
Depreciation, Depletion And Amortization	$414.0K	$255.0K	$887.0K
YoY Change	216.03%	96.15%	58.11%
Cash From Operating Activities	-$4.214M	-$3.644M	-$14.69M
YoY Change	0.19%	18.5%	31.66%
INVESTING ACTIVITIES
Capital Expenditures	$42.00K	$53.00K	$194.0K
YoY Change		5200.0%	228.81%
Acquisitions
YoY Change
Other Investing Activities		-$4.981M	-$4.981M
YoY Change
Cash From Investing Activities	-$42.00K	-$5.034M	-$5.175M
YoY Change		-503500.0%	8671.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$0.00
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-$4.214M	-3.644M	-$14.69M
Cash From Investing Activities	-$42.00K	-5.034M	-$5.175M
Cash From Financing Activities	$0.00	0.000	$0.00
Net Change In Cash	-$4.248M	-8.678M	-$19.88M
YoY Change	0.43%	182.3%	-172.18%
FREE CASH FLOW
Cash From Operating Activities	-$4.214M	-$3.644M	-$14.69M
Capital Expenditures	$42.00K	$53.00K	$194.0K
Free Cash Flow	-$4.256M	-$3.697M	-$14.88M
YoY Change	1.19%	20.19%	32.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37854
CY2022	dei	Entity Registrant Name EntityRegistrantName	Ekso Bionics Holdings, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-0367049
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	101 Glacier Point
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite A
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Rafael
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94901
CY2022	dei	City Area Code CityAreaCode	510
CY2022	dei	Local Phone Number LocalPhoneNumber	984-1761
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	18860934	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13341505	shares
CY2022	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2022	dei	Auditor Location AuditorLocation	San Francisco, California
CY2022	dei	Auditor Firm AuditorFirmId	100
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20525000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40406000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	28000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4625000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4662000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5187000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2242000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	700000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	485000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	31037000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	47795000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2680000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	991000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1307000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	216000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5217000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	431000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	231000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	164000	usd
CY2022Q4	us-gaap	Assets Assets	40903000	usd
CY2021Q4	us-gaap	Assets Assets	49166000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3151000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3107000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2278000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2299000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1121000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1220000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2310000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	341000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	229000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9201000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6855000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1032000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1475000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	3767000	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1993000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1087000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	233000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1550000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	141000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	74000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	15461000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	11947000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13203000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13203000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12693000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12693000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	248813000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	246090000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	563000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223947000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208867000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	25442000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37219000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40903000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49166000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12912000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11246000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6698000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4497000	usd
CY2022	us-gaap	Gross Profit GrossProfit	6214000	usd
CY2021	us-gaap	Gross Profit GrossProfit	6749000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7157000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7305000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3626000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2549000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10987000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10723000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	21770000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	20577000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15556000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13828000	usd
CY2022	us-gaap	Interest Expense InterestExpense	156000	usd
CY2021	us-gaap	Interest Expense InterestExpense	113000	usd
CY2022	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	1317000	usd
CY2021	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	3962000	usd
CY2022	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	usd
CY2021	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	1099000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-655000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-867000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	476000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4064000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15080000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9764000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	580000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	830000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14500000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8934000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12962000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12193000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12962000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12269000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4434000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9764000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	35360000	usd
CY2021	ekso	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3878000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	152000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2329000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	830000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37219000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15080000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	177000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2546000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	580000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	25442000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15080000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9764000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	887000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1023000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	33000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	75000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1099000	usd
CY2022	ekso	Common Stock Contribution CommonStockContribution	186000	usd
CY2021	ekso	Common Stock Contribution CommonStockContribution	171000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2546000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2329000	usd
CY2022	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	1317000	usd
CY2021	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	3962000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	18000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-134000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-655000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-867000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	67000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1624000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1400000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	752000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	303000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-19000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-102000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1612000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-197000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	379000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-511000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-564000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14688000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11156000	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	5000000	usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	194000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	19000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5175000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37295000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1417000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38712000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-18000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19881000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27544000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40406000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12862000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20525000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40406000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	126000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	104000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2022	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	0	usd
CY2021	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	2461000	usd
CY2022	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	176000	usd
CY2021	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	152000	usd
CY2022	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	385000	usd
CY2021	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	434000	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	4055000	usd
CY2021	us-gaap	Notes Issued1 NotesIssued1	0	usd
CY2022	ekso	Fair Value Of Warrants Issued Upon Equity Financing FairValueOfWarrantsIssuedUponEquityFinancing	0	usd
CY2021	ekso	Fair Value Of Warrants Issued Upon Equity Financing FairValueOfWarrantsIssuedUponEquityFinancing	1936000	usd
CY2022	ekso	Operating Leases Liability Right Of Use Asset Initial Recognition OperatingLeasesLiabilityRightOfUseAssetInitialRecognition	1459000	usd
CY2021	ekso	Operating Leases Liability Right Of Use Asset Initial Recognition OperatingLeasesLiabilityRightOfUseAssetInitialRecognition	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223947000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14688000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20525000	usd
CY2022Q4	ekso	Debt Covenant Covenant Compliance Unrestricted Cash DebtCovenantCovenantComplianceUnrestrictedCash	2000000	usd
CY2022	ekso	Unrestricted Cash UnrestrictedCash	18525000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company reclassified the amortization of operating lease right-of-use assets in its consolidated statements of cash flows. Amounts amortized related to operating lease right-of-use assets have been reclassified to "Depreciation and amortization" from "Prepaid expenses and other assets, current and noncurrent" as applicable. Accordingly, prior period amounts have been reclassified to conform to the current period presentation, in all material respects. These reclassifications did not affect changes in cash flow used in operating activities or net (decrease) in cash for the year ended December 31, 2021.</span></div>For the year ended December 31, 2022, the Company reclassified certain expenses presented in the consolidated statement operations and comprehensive loss. Amounts associated with the maintenance of patents which had previously been presented as research and development operating expenses have been reclassified to general and administrative operating expenses. Accordingly, prior period amounts of $175 for the year ended 2022 and $199 for the year ended 2021, have been reclassified to conform to the current period presentation, in all material respects. These reclassifications did not affect total operating expenses, net operating loss, or net loss for the year ended December 31, 2022 and December 31, 2021.
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1121000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	579000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	453000	usd
CY2022Q4	ekso	Contractwith Customer Liability Non Cancellable Backlog ContractwithCustomerLiabilityNonCancellableBacklog	2288000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, assets acquired and liabilities assumed in business combinations, revenue recognition, deferred revenue, the valuation of warrants and employee equity awards, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2022 and 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div>
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1032000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1475000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2695000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3302000	usd
CY2022	ekso	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	1397000	usd
CY2021	ekso	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	1189000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3837000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2061000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	487000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	145000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	863000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	36000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5187000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2242000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1939000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15080000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9764000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1029000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15080000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10793000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12962000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12193000	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	76000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12962000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12269000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2893000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2066000	shares
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1796000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2153000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2695000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2153000	usd
CY2022Q4	ekso	Contract With Customer Liability Extended Maintenance And Support ContractWithCustomerLiabilityExtendedMaintenanceAndSupport	2124000	usd
CY2021Q4	ekso	Contract With Customer Liability Extended Maintenance And Support ContractWithCustomerLiabilityExtendedMaintenanceAndSupport	2349000	usd
CY2022Q4	ekso	Contract With Customer Liability Royalties ContractWithCustomerLiabilityRoyalties	0	usd
CY2021Q4	ekso	Contract With Customer Liability Royalties ContractWithCustomerLiabilityRoyalties	280000	usd
CY2022Q4	ekso	Contract With Customer Liability Devices And Advances ContractWithCustomerLiabilityDevicesAndAdvances	29000	usd
CY2021Q4	ekso	Contract With Customer Liability Devices And Advances ContractWithCustomerLiabilityDevicesAndAdvances	66000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2153000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2695000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1121000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1220000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12912000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11246000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5677000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5730000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2997000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4739000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2680000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	991000	usd
CY2022	us-gaap	Depreciation Depreciation	486000	usd
CY2021	us-gaap	Depreciation Depreciation	561000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1843000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2015000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	274000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	195000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	161000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	89000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2278000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2299000	usd
CY2022	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa (EMEA), and one or two years in the Asia Pacific (APAC) region.
CY2021Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	431000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	431000	usd
CY2022Q4	us-gaap	Below Market Lease Gross BelowMarketLeaseGross	20000	usd
CY2022Q4	us-gaap	Below Market Lease Accumulated Amortization BelowMarketLeaseAccumulatedAmortization	0	usd
CY2022Q4	us-gaap	Below Market Lease Net BelowMarketLeaseNet	20000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5240000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5217000	usd
CY2022	ekso	Below Market Lease Amortization Period BelowMarketLeaseAmortizationPeriod	P1Y
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	325000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	306000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	345000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	345000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	345000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1241000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2907000	usd
CY2020Q3	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1512000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20525000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	408000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	420000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	401000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	349000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1578000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	150000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1428000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	341000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1087000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1428000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	605000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	527000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	186000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	171000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13203000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13203000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	38.93
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1240000	shares
CY2022	ekso	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	0	shares
CY2022	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	0	shares
CY2022	ekso	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1240000	shares
CY2022	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	0	usd
CY2021	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	1417000	usd
CY2022	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	0	shares
CY2021	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	358000	shares
CY2022	ekso	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	0	shares
CY2021	ekso	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	300000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.06
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	137000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	111000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	67000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	293000	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	233000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	333000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	800000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	550000	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	428000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1194000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	57000	usd
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	270000	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y3M3D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	37.96
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	261000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2546000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2329000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13749000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9069000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1331000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-695000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15080000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9764000	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.151
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.313
CY2022	ekso	Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant	0.018
CY2021	ekso	Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant	0.085
CY2022	ekso	Effective Income Tax Rate Reconciliation Loan Forgiveness EffectiveIncomeTaxRateReconciliationLoanForgiveness	0
CY2021	ekso	Effective Income Tax Rate Reconciliation Loan Forgiveness EffectiveIncomeTaxRateReconciliationLoanForgiveness	0.024
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.077
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.009
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	249000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	257000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48829000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47579000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2034000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1899000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	356000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	395000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	640000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	213000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	377000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1670000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2763000	usd
CY2022Q4	ekso	Deferred Tax Assets Operating Lease Right Of Use Asset DeferredTaxAssetsOperatingLeaseRightOfUseAsset	236000	usd
CY2021Q4	ekso	Deferred Tax Assets Operating Lease Right Of Use Asset DeferredTaxAssetsOperatingLeaseRightOfUseAsset	30000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	22000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	20000	usd
CY2022Q4	ekso	Deferred Tax Liabilities Operating Lease Liability DeferredTaxLiabilitiesOperatingLeaseLiability	208000	usd
CY2021Q4	ekso	Deferred Tax Liabilities Operating Lease Liability DeferredTaxLiabilitiesOperatingLeaseLiability	28000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	41000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	32000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54000000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53260000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	740000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4587000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	3300000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	668000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	645000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	48000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	22000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	716000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	668000	usd
CY2022Q4	ekso	Number Of License Agreements NumberOfLicenseAgreements	2	license_agreement
CY2022Q4	ekso	Number Of License Agreements NumberOfLicenseAgreements	2	license_agreement
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	20000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	3480000	usd
CY2022	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P1Y
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1578000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	8685000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	2828000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	3321000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	2536000	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12912000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6698000	usd
CY2022	us-gaap	Gross Profit GrossProfit	6214000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11246000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4497000	usd
CY2021	us-gaap	Gross Profit GrossProfit	6749000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12912000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11246000	usd

Files In Submission

Name	View Source	Status
ekso-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ekso-20221231_def.xml	Edgar Link	unprocessable
0001549084-23-000011-index-headers.html	Edgar Link	pending
0001549084-23-000011-index.html	Edgar Link	pending
0001549084-23-000011.txt	Edgar Link	pending
0001549084-23-000011-xbrl.zip	Edgar Link	pending
ekso-20221231.htm	Edgar Link	pending
ekso-20221231.xsd	Edgar Link	pending
exhibit101112312022.htm	Edgar Link	pending
exhibit1014123122.htm	Edgar Link	pending
exhibit1014123122001.jpg	Edgar Link	pending
exhibit1014123122002.jpg	Edgar Link	pending
exhibit1014123122003.jpg	Edgar Link	pending
exhibit1014123122004.jpg	Edgar Link	pending
exhibit1014123122005.jpg	Edgar Link	pending
exhibit1014123122006.jpg	Edgar Link	pending
exhibit1014123122007.jpg	Edgar Link	pending
exhibit1014123122008.jpg	Edgar Link	pending
exhibit1014123122009.jpg	Edgar Link	pending
exhibit1014123122010.jpg	Edgar Link	pending
exhibit1014123122011.jpg	Edgar Link	pending
exhibit1014123122012.jpg	Edgar Link	pending
exhibit1014123122013.jpg	Edgar Link	pending
exhibit1015123122.htm	Edgar Link	pending
exhibit1015123122001.jpg	Edgar Link	pending
exhibit1015123122002.jpg	Edgar Link	pending
exhibit1015123122003.jpg	Edgar Link	pending
exhibit1015123122004.jpg	Edgar Link	pending
exhibit1015123122005.jpg	Edgar Link	pending
exhibit1015123122006.jpg	Edgar Link	pending
exhibit1015123122007.jpg	Edgar Link	pending
exhibit1015123122008.jpg	Edgar Link	pending
exhibit1015123122009.jpg	Edgar Link	pending
exhibit1016123122.htm	Edgar Link	pending
exhibit1016123122001.jpg	Edgar Link	pending
exhibit1016123122002.jpg	Edgar Link	pending
exhibit1022123122.htm	Edgar Link	pending
exhibit1022123122001.jpg	Edgar Link	pending
exhibit1022123122002.jpg	Edgar Link	pending
exhibit1022123122003.jpg	Edgar Link	pending
exhibit1022123122004.jpg	Edgar Link	pending
exhibit1022123122005.jpg	Edgar Link	pending
exhibit1022123122006.jpg	Edgar Link	pending
exhibit1022123122007.jpg	Edgar Link	pending
exhibit1022123122008.jpg	Edgar Link	pending
exhibit1023123122.htm	Edgar Link	pending
exhibit1023123122001.jpg	Edgar Link	pending
exhibit1023123122002.jpg	Edgar Link	pending
ekso-20221231_htm.xml	Edgar Link	completed
exhibit1023123122003.jpg	Edgar Link	pending
exhibit1023123122004.jpg	Edgar Link	pending
exhibit21112312022.htm	Edgar Link	pending
exhibit23112312022.htm	Edgar Link	pending
exhibit31112312022.htm	Edgar Link	pending
exhibit31212312022.htm	Edgar Link	pending
exhibit32112312022.htm	Edgar Link	pending
exhibit32212312022.htm	Edgar Link	pending
exhibit41012312022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_2.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
image_4.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ekso-20221231_pre.xml	Edgar Link	unprocessable
ekso-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2023 Q1 Form 10-K Financial Statement

#000154908423000011 Filed on March 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2023 Q1 Form 10-K Financial Statement

#000154908423000011 Filed on March 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso